Home Archives July 2008 State wins case against Merck

State wins case against Merck

| Print |  Email
Tuesday, July 01, 2008

STATEWIDE Oregon’s lead role in a record-breaking settlement with Merck & Co. over deceptive marketing for the anti-inflammatory drug Vioxx represents the latest skirmish in an ongoing campaign against Big Pharma that has earned the state more than $8.5 million.

After leading a three-year, 30-state investigation into deceptive advertisements downplaying the health risks associated with Vioxx, Oregon received $2.8 million of the record $58 million paid out by Merck. The judgment banned Merck from manipulating data when marketing to physicians, “ghost writing” articles for medical journals and failing to disclose conflicts of interest among doctors who study and promote drugs on behalf of the company.

The Vioxx settlement reflects growing concerns over how drug companies hook consumers on prescription drugs. Drug giants have poured billions into “demand creation” since the federal government loosened rules prohibiting “direct-to-consumer” advertising in 1997. In 2007 Oregon was the lead state in an $8 million settlement against Bayer for minimizing the dangers of Baycol, and also was in on a $19.5 million settlement against Purdue Pharma regarding OxyContin.

State officials cannot comment about current cases involving major pharmaceutical firms, but Oregon’s campaign against Big Pharma is clearly far from finished. Leading the way has been assistant attorney general David Hart, who worked in health care prior to pursuing consumer law and is married to a pharmacist. Hart has served as lead investigator and negotiator on all of Oregon’s major drug company cases. “The money we’ve gotten in these settlements gets put to good use, but these cases aren’t about the money,” he says, “they’re about the rules we create and the light that we shed on these practices so that we can change them.”

Ken Johnson, vice president of the Pharmaceutical Research and Manufacturers of America, said in a prepared statement that drug companies “are committed to providing accurate, educational information to patients and health professionals about their medicines.”


BEN JACKLET


To comment, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

 

More Articles

Shipping News

September 2014
Tuesday, August 26, 2014
BY JENNIFER MARGULIS

In 2012 The Dalles, a city of some 14,400 located 75 miles east of Portland and often seen as the poor cousin to adjacent Hood River, completed a massive project to revitalize its dock.


Read more...

Podcast: Interview with Steve Balzac

Contributed Blogs
Tuesday, August 19, 2014

082014BalzacBY TOM COX | OB BLOGGER

Tom Cox interviews Steve Balzac, author of "Organizational Psychology for Managers."


Read more...

Constant Contact

October 2014
Thursday, September 25, 2014
BY AMY MILSHTEIN

To prevent burnout, companies are banning email and after-hours communications. But is the 24-hour workday here to stay?


Read more...

College Conundrum

October 2014
Thursday, September 25, 2014
BY KIM MOORE

University and college tuition fees have been rising for more than a decade, while state funds for higher education have steadily declined.


Read more...

The Diaspora

October 2014
Thursday, September 25, 2014
BY LEE VAN DER VOO

Former newspaper journalists move into brand journalism.


Read more...

Is this employee right?

Contributed Blogs
Wednesday, August 13, 2014
081314 thumb employeefeelingsBY TOM COX | OB BLOGGER

When I say, “Your Employee is Always Right,” I do not mean “right about the facts,” but rather “right about how they feel” and “right about how they want to be led.”


Read more...

Buyer's Remorse

September 2014
Tuesday, August 26, 2014

Parents and students paying for college today are like homeowners who bought a house just before the housing bubble burst.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS